COVID-19 vaccination and pregnancy-induced hypertension risk in women undergoing assisted reproduction
Human Reproduction · 2025
DOI: 10.1093/humrep/deaf055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, 2025. Verfasst von Shujuan Ma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center for Reproduction and Genetics in Hunan Province, Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha, Hunan, China. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19, Hypertension, Pregnancy-Induced, Reproductive Techniques, Assisted. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Hunan High-Level Talent Aggregation Project, National Natural Science Foundation of China, Hunan Provincial Enterprise Joint Fund.
Abstract (Originalsprache)
STUDY QUESTION Does COVID-19 vaccination affect the risk of pregnancy-induced hypertension (PIH) in women undergoing ARTs, and does this risk differ based on vaccine type (inactivated vs recombinant) and timing relative to embryo transfer? SUMMARY ANSWER Women who received inactivated COVID-19 vaccines before undergoing ART had a significantly increased risk of developing PIH, particularly when vaccinated with two or more doses or when embryo transfer occurred within 1 month of vaccination. WHAT IS KNOWN ALREADY COVID-19 vaccination during pregnancy reduces the risk of severe COVID-19 illness with no significant safety concerns for the mother or fetus. PIH is a common complication in ART pregnancies, particularly in older women and those with higher BMI, but the effects of different COVID-19 vaccine types on PIH risk in ART pregnancies remain unclear. STUDY DESIGN, SIZE, DURATION A retrospective cohort study analyzing 3911 women undergoing ART after receiving COVID-19 vaccines. The study period spanned from 1 December 2020 to 30 September 2022. PARTICIPANTS/MATERIALS, SETTING, METHODS Participants were categorized based on COVID-19 vaccination status, vaccine type (inactivated vs recombinant), and the timing of vaccination relative to embryo transfer. The primary outcome was the development of PIH. Multivariate robust Poisson regression was used to assess the association between vaccination and PIH, while subgroup analyses explored the risk across variables like age, BMI, and embryo transfer type. MAIN RESULTS AND THE ROLE OF CHANCE Women vaccinated with an inactivated COVID-19 vaccine prior to embryo transfer had a significantly higher incidence of PIH compared to unvaccinated counterparts (relative risk [RR] = 1.45; 95% CI 1.10–1.92; P = 0.009). In contrast, recombinant vaccines did not show a significant association with increased PIH risk (RR = 1.19; 95% CI 0.69–2.05; P = 0.537). The risk was particularly pronounced among women receiving two or more doses of the inactivated vaccines and those who had embryo transfers within 1 month of vaccination. Subgroup analyses showed elevated PIH risk in women aged ≥30 years old, those with BMI ≥22 kg/m2, individuals with secondary infertility, and those undergoing cleavage-stage or fresh embryo transfers. LIMITATIONS, REASONS FOR CAUTION The study’s retrospective design limits causal inference. The sample is from a single ethnic background, and familial hypertension history was not available, potentially introducing residual confounding. WIDER IMPLICATIONS OF THE FINDINGS The study suggests that the type and timing of COVID-19 vaccination may influence PIH risk in ART pregnancies. These findings underscore the need for careful consideration of vaccination type and timing in ART protocols and highlight the importance of further prospective studies to validate these results before influencing clinical decision-making. STUDY FUNDING/COMPETING INTEREST(S) This work was supported by the Hunan High-Level Talent Aggregation Project [2022RC4007]; the National Natural Science Foundation of China [72004148]; the Hunan Provincial Enterprise Joint Fund [2024JJ9093]; the Hunan Provincial Grant for Innovative Province Construction [2019SK4012]; the Deutschlandstipendium of the Charite; the non-restricted research grant of Boehringer Ingelheim Ltd.; and the Research Grant of CITIC-Xiangya [YNXM-202304, 202217]. The authors report no conflicts of interest. TRIAL REGISTRATION NUMBER N/A.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Center for Reproduction and Genetics in Hunan Province, Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha, Hunan, China.
- Key Laboratory of Reproductive and Stem Cell Engineering, Central South University, Changsha, Hunan, China.
- Hunan Key Laboratory of Viral Hepatitis, Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Immunization Program Department, Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China.
- Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
ORCID-Profile: Mingli Fang, Fei Gong, Berthold Hocher
Förderung
- Hunan High-Level Talent Aggregation Project
- National Natural Science Foundation of China
- Hunan Provincial Enterprise Joint Fund
Zitieren
APA
Ma, S., Zheng, Y., Fang, M., Xiong, Y., Hu, L., Liu, Y., Gong, F., Krämer, B. K., Lin, G., & Hocher, B. (2025). COVID-19 vaccination and pregnancy-induced hypertension risk in women undergoing assisted reproduction. Human Reproduction. https://doi.org/10.1093/humrep/deaf055
Vancouver
Ma S, Zheng Y, Fang M, Xiong Y, Hu L, Liu Y, et al. COVID-19 vaccination and pregnancy-induced hypertension risk in women undergoing assisted reproduction. Human Reproduction. 2025. doi:10.1093/humrep/deaf055
BibTeX
@article{Ma2025,
author = {Ma, Shujuan and Zheng, Yixiang and Fang, Mingli and Xiong, Yiquan and Hu, Liang and Liu, Yvonne and Gong, Fei and Krämer, Bernhard K and Lin, Ge and Hocher, Berthold},
title = {COVID-19 vaccination and pregnancy-induced hypertension risk in women undergoing assisted reproduction},
journal = {Human Reproduction},
year = {2025},
doi = {10.1093/humrep/deaf055}
}
EUVIMED